Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.8532.2700
Address
4-6 Southampton Crescent Abbotsford, Victoria (VIC) 3067
Description
Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its pipeline and products include SN38, cabazitaxel, docetaxel, radiopharmaceuticals, antibody-drug conjugates, and anti-infective products. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.09 - 0.14
Trade Value (12mth)
AU$12,548.00
1 week
-7.29%
1 month
-8.25%
YTD
-19.09%
1 year
-34.07%
All time high
2.52
EPS 3 yr Growth
-60.20%
EBITDA Margin
-169.40%
Operating Cashflow
-$7m
Free Cash Flow Return
-20.60%
ROIC
-24.10%
Interest Coverage
N/A
Quick Ratio
4.60
Shares on Issue (Fully Dilluted)
416m
HALO Sector
Healthcare
Next Company Report Date
20-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.16
Date | Announcements |
---|---|
04 April 25 |
Application for quotation of securities - SPL
×
Application for quotation of securities - SPL |
04 April 25 |
Notification of cessation of securities - SPL
×
Notification of cessation of securities - SPL |
17 March 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
26 February 25 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
29 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
16 January 25 |
DEP Presentation at Targeted Radio Therapies Conference
×
DEP Presentation at Targeted Radio Therapies Conference |
19 December 24 |
SPL receives positive FDA feedback on DEP SN38 for PROC
×
SPL receives positive FDA feedback on DEP SN38 for PROC |
12 December 24 |
Notification regarding unquoted securities - SPL
×
Notification regarding unquoted securities - SPL |
12 December 24 |
Change of Director's Interest Notice - Ms Cheryl Maley
×
Change of Director's Interest Notice - Ms Cheryl Maley |
04 December 24 |
DEP Presentation at Radiopharmaceuticals Summit
×
DEP Presentation at Radiopharmaceuticals Summit |
29 November 24 |
Results of 2024 Reconvened Annual General Meeting
×
Results of 2024 Reconvened Annual General Meeting |
27 November 24 |
AGM Notice of Reconvened Meeting
×
AGM Notice of Reconvened Meeting |
26 November 24 |
AGM Chair's address and CEO's presentation
×
AGM Chair's address and CEO's presentation |
26 November 24 |
Results of 2024 Annual General Meeting
×
Results of 2024 Annual General Meeting |
21 November 24 |
DEP SN38 Results Showcased at GI Cancer Conference
×
DEP SN38 Results Showcased at GI Cancer Conference |
18 November 24 |
Bell Potter Healthcare Conference Presentation
×
Bell Potter Healthcare Conference Presentation |
06 November 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
01 November 24 |
Notification regarding unquoted securities - SPL
×
Notification regarding unquoted securities - SPL |
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 October 24 |
Australian Microcap Conference Presentation
×
Australian Microcap Conference Presentation |
28 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
25 October 24 |
Application for quotation of securities - SPL
×
Application for quotation of securities - SPL |
24 October 24 |
Change of Director's Interest Notice - R Thomas
×
Change of Director's Interest Notice - R Thomas |
18 October 24 |
SPL7013 Nasal Spray Australia Update
×
SPL7013 Nasal Spray Australia Update |
03 October 24 |
Notification of cessation of securities - SPL
×
Notification of cessation of securities - SPL |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.